BJUI Mini Reviews - Key targets of hormonal treatment of prostate cancer. Part 2: The androgen receptor and 5α-reductase
The objective of this review is to provide an understanding of the pharmacological properties and the potential clinical benefits of 5AR inhibition in prostate cancer treatment.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2009 UroToday ® All Rights Reserved |
